Plus Therapeutics, Inc. (PSTV)
After hours:
| Previous close | 1.2400 |
| Open | 1.2500 |
| Bid | 1.2400 x 900 |
| Ask | 1.2600 x 800 |
| Day's range | 1.2100 - 1.2500 |
| 52-week range | 1.1800 - 10.9500 |
| Volume | |
| Avg. volume | 426,490 |
| Market cap | 3.6M |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.5400 |
| Earnings date | 18 Oct 2023 - 23 Oct 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.50 |
GlobeNewswirePlus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
CNSide™ assay is the gold standard diagnostic cerebrospinal fluid (CSF) assay for patients with suspected central nervous system (CNS) cancers As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy AUSTIN, Texas, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for cent
- GlobeNewswire
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
AUSTIN, Texas, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced treatment of the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors. “The Phase 1/Pa
- GlobeNewswire
Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 3:00 p.m. ET at the Lotte New York Palace in New York, NY. Investors i
